1420477-60-6

Acalabrutinib (ACP-196), also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.

Acalabrutinib-[D4] (Standard) is a reference standard of Acalabrutinib-[D4] intended for quantitative analysis, quality control, and related biochemical research applications.

Acalabrutinib enantiomer (R-Acalabrutinib) is a chemical compound that belongs to the class of Bruton's tyrosine kinase (BTK) inhibitors. Acarabitinib enantiomers can be used in the study of cancer, autoimmune diseases and chronic inflammation.

Acalabrutinib-D4 is a deuterated compound of Acalabrutinib. Acalabrutinib (T3626) has a CAS number of 1420477-60-6. Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.